Switch to:
Also traded in: Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.02
UHS's Cash-to-Debt is ranked lower than
95% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. UHS: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
UHS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.02 Max: 0.27
Current: 0.02
0
0.27
Equity-to-Asset 0.46
UHS's Equity-to-Asset is ranked lower than
55% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. UHS: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
UHS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.42 Max: 0.55
Current: 0.46
0.26
0.55
Debt-to-Equity 0.86
UHS's Debt-to-Equity is ranked lower than
63% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 0.57 vs. UHS: 0.86 )
Ranked among companies with meaningful Debt-to-Equity only.
UHS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23  Med: 0.71 Max: 1.98
Current: 0.86
0.23
1.98
Interest Coverage 10.71
UHS's Interest Coverage is ranked higher than
58% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.41 vs. UHS: 10.71 )
Ranked among companies with meaningful Interest Coverage only.
UHS' s Interest Coverage Range Over the Past 10 Years
Min: 5.19  Med: 9.13 Max: 48.57
Current: 10.71
5.19
48.57
Piotroski F-Score: 7
Altman Z-Score: 2.50
Beneish M-Score: -2.52
WACC vs ROIC
5.80%
9.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 12.62
UHS's Operating Margin % is ranked higher than
68% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. UHS: 12.62 )
Ranked among companies with meaningful Operating Margin % only.
UHS' s Operating Margin % Range Over the Past 10 Years
Min: 7.91  Med: 13.04 Max: 13.93
Current: 12.62
7.91
13.93
Net Margin % 7.10
UHS's Net Margin % is ranked higher than
64% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. UHS: 7.10 )
Ranked among companies with meaningful Net Margin % only.
UHS' s Net Margin % Range Over the Past 10 Years
Min: 3.64  Med: 6.13 Max: 7.53
Current: 7.1
3.64
7.53
ROE % 15.74
UHS's ROE % is ranked higher than
72% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 9.35 vs. UHS: 15.74 )
Ranked among companies with meaningful ROE % only.
UHS' s ROE % Range Over the Past 10 Years
Min: 11.67  Med: 15.9 Max: 18.6
Current: 15.74
11.67
18.6
ROA % 7.10
UHS's ROA % is ranked higher than
72% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. UHS: 7.10 )
Ranked among companies with meaningful ROA % only.
UHS' s ROA % Range Over the Past 10 Years
Min: 4.01  Med: 5.89 Max: 7.32
Current: 7.1
4.01
7.32
ROC (Joel Greenblatt) % 27.33
UHS's ROC (Joel Greenblatt) % is ranked higher than
67% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 16.07 vs. UHS: 27.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UHS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.97  Med: 23.03 Max: 28.88
Current: 27.33
15.97
28.88
3-Year Revenue Growth Rate 10.20
UHS's 3-Year Revenue Growth Rate is ranked higher than
59% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. UHS: 10.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UHS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.2  Med: 10.4 Max: 19.4
Current: 10.2
-4.2
19.4
3-Year EBITDA Growth Rate 11.40
UHS's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. UHS: 11.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UHS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.3  Med: 13.8 Max: 26.7
Current: 11.4
-3.3
26.7
3-Year EPS without NRI Growth Rate 11.60
UHS's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 7.50 vs. UHS: 11.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UHS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 20.5 Max: 73.8
Current: 11.6
-11.3
73.8
GuruFocus has detected 1 Warning Sign with Universal Health Services Inc $UHS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UHS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

UHS Guru Trades in Q3 2016

Larry Robbins 950,390 sh (New)
Andreas Halvorsen 1,929,192 sh (New)
Jana Partners 1,273,646 sh (New)
Jim Simons 248,900 sh (+130.25%)
Lee Ainslie 4,584,358 sh (+65.56%)
Robert Olstein 34,000 sh (+41.67%)
Vanguard Health Care Fund 3,939,340 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Private Capital 119,170 sh (-2.18%)
Ron Baron 189,684 sh (-3.02%)
Joel Greenblatt 295,558 sh (-11.64%)
Paul Tudor Jones 2,200 sh (-38.39%)
» More
Q4 2016

UHS Guru Trades in Q4 2016

Paul Tudor Jones 12,393 sh (+463.32%)
Larry Robbins 1,762,915 sh (+85.49%)
Robert Olstein 57,000 sh (+67.65%)
Jana Partners 2,051,970 sh (+61.11%)
Lee Ainslie 6,130,994 sh (+33.74%)
Vanguard Health Care Fund 4,527,240 sh (+14.92%)
Private Capital 109,139 sh (-8.42%)
Ron Baron 156,224 sh (-17.64%)
Joel Greenblatt 182,778 sh (-38.16%)
Andreas Halvorsen 350,693 sh (-81.82%)
Jim Simons 16,400 sh (-93.41%)
» More
Q1 2017

UHS Guru Trades in Q1 2017

Steven Cohen 108,830 sh (New)
Andreas Halvorsen 1,728,658 sh (+392.93%)
Jana Partners 2,449,017 sh (+19.35%)
Ron Baron 156,224 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Private Capital 107,870 sh (-1.16%)
Larry Robbins 1,714,464 sh (-2.75%)
Vanguard Health Care Fund 4,289,109 sh (-5.26%)
Lee Ainslie 4,952,724 sh (-19.22%)
Robert Olstein 41,000 sh (-28.07%)
Paul Tudor Jones 7,674 sh (-38.08%)
» More
Q2 2017

UHS Guru Trades in Q2 2017

Jim Simons 517,200 sh (New)
David Dreman 153 sh (New)
Steven Cohen 180,400 sh (+65.76%)
Paul Tudor Jones 10,825 sh (+41.06%)
Larry Robbins 1,973,545 sh (+15.11%)
Lee Ainslie 5,426,487 sh (+9.57%)
Robert Olstein 44,000 sh (+7.32%)
Andreas Halvorsen 1,742,195 sh (+0.78%)
Private Capital 107,620 sh (-0.23%)
Vanguard Health Care Fund 4,225,410 sh (-1.49%)
Ron Baron 150,734 sh (-3.51%)
Jana Partners 1,360,628 sh (-44.44%)
» More
» Details

Insider Trades

Latest Guru Trades with UHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.02%$112.33 - $125.07 $ 108.43-9%4,225,410
Ron Baron 2017-06-30 Reduce -3.51%$112.33 - $125.07 $ 108.43-9%150,734
Private Capital 2017-06-30 Reduce -0.23%$112.33 - $125.07 $ 108.43-9%107,620
Robert Olstein 2017-06-30 Add 7.32%0.05%$112.33 - $125.07 $ 108.43-9%44,000
David Dreman 2017-06-30 New Buy0.01%$112.33 - $125.07 $ 108.43-9%153
Vanguard Health Care Fund 2017-03-31 Reduce -5.26%0.06%$106.71 - $126.65 $ 108.43-8%4,289,109
Private Capital 2017-03-31 Reduce -1.16%0.02%$106.71 - $126.65 $ 108.43-8%107,870
Robert Olstein 2017-03-31 Reduce -28.07%0.22%$106.71 - $126.65 $ 108.43-8%41,000
Joel Greenblatt 2017-03-31 Sold Out 0.25%$106.71 - $126.65 $ 108.43-8%0
Vanguard Health Care Fund 2016-12-31 Add 14.92%0.15%$101.55 - $128.06 $ 108.43-8%4,527,240
Joel Greenblatt 2016-12-31 Reduce -38.16%0.18%$101.55 - $128.06 $ 108.43-8%182,778
Ron Baron 2016-12-31 Reduce -17.64%0.02%$101.55 - $128.06 $ 108.43-8%156,224
Private Capital 2016-12-31 Reduce -8.42%0.18%$101.55 - $128.06 $ 108.43-8%109,139
Robert Olstein 2016-12-31 Add 67.65%0.31%$101.55 - $128.06 $ 108.43-8%57,000
Joel Greenblatt 2016-09-30 Reduce -11.64%0.06%$118.82 - $138.28 $ 108.43-14%295,558
Ron Baron 2016-09-30 Reduce -3.02%$118.82 - $138.28 $ 108.43-14%189,684
Private Capital 2016-09-30 Reduce -2.18%0.05%$118.82 - $138.28 $ 108.43-14%119,170
Robert Olstein 2016-09-30 Add 41.67%0.16%$118.82 - $138.28 $ 108.43-14%34,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 622110    SIC: 8062
Compare:NYSE:DVA, NAS:WOOF, NYSE:EVHC, NYSE:HLS, NAS:ACHC, NYSE:MD, NYSE:CHE, NYSE:SEM, NAS:LPNT, NYSE:AMN, NAS:AMED, NYSE:THC, NAS:TVTY, NAS:LHCG, NYSE:CYH, NYSE:USPH, NAS:PRSC, NAS:AFAM, NAS:SGRY, NAS:ADUS » details
Traded in other countries:UHS.Germany, UHID.USA,
Headquarter Location:USA
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers.

Universal Health Services owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers. Each segment contributes roughly half of the firm's overall revenue. Universal Health Services receives a significant portion of its net patient revenue from Medicare and Medicaid. The largest proportion of the firm's net patient revenue is paid by managed care organizations.

Top Ranked Articles about Universal Health Services Inc

Universal Health Services, Inc. To Present At The Baird's 2017 Global Healthcare Conference
Universal Health Services, Inc. Announces Dividend
Universal Health Services, Inc. Announces Date For Second Quarter 2017 Earnings Release And Conference Call
Universal Health Services, Inc. To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
Universal Health Services, Inc. To Present At The UBS Global Healthcare Conference
Universal Health Services, Inc. To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
Universal Health Services, Inc. to Present at the Deutsche Bank 42nd Annual Healthcare Conference
Universal Health Services, Inc. Announces Date For First Quarter 2017 Earnings Release And Conference Call
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Universal Health Services, Inc. (UHS) and Lead Plaintiff Deadline: February 21, 2017

NEW YORK, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Universal Health Services, Inc. (“Universal Health” or the “Company”) (NYSE:NYSE:UHS) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Universal Health securities from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/uhs. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not the patient’s medical needs; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to bill for the maximum of its services; (3) accordingly, Universal Health’s revenues from inpatient care relied on unjustifiable practices; (4) due to the aforementioned, Universal Health lacked efficient internal control regarding its practices and policies of admitting patients; and (5) consequently, Universal Health’s public statements were materially false and misleading at all relevant times. On December 7, 2016 BuzzFeed released its investigation into Universal Health “…based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents.” BuzzFeed reported that “[c]urrent and former employees from at least 10 UHS hospitals in nine states said they were under pressure to fill beds by almost any method – which sometimes meant exaggerating people’s symptoms or twisting their words to make them seem suicidal – and to hold them until their insurance payments ran out.” Following this news, Universal Health stock dropped $15.01 per share or nearly 12% to close at $111.36 on December 7, 2016. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/uhs  or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Universal Health you have until February 21, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
UNIVERSAL HEALTH 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Universal Health Services, Inc. – (UHS)
NEW ORLEANS, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until February 21, 2017 to file lead plaintiff applications in a securities class action lawsuit against Universal Health Services, Inc. (NYSE:NYSE:UHS). Investor losses must relate to purchases of the Company’s shares between February 26, 2015 and December 7, 2016.  This action is pending in the United States District Court for the Central District of California.What You May DoIf you purchased securities of Universal Health and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by February 21, 2017. About Kahn Swick & Foti, LLCKSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...

Ratios

vs
industry
vs
history
PE Ratio 14.75
UHS's PE Ratio is ranked higher than
80% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 26.05 vs. UHS: 14.75 )
Ranked among companies with meaningful PE Ratio only.
UHS' s PE Ratio Range Over the Past 10 Years
Min: 8.1  Med: 15.17 Max: 23.97
Current: 14.75
8.1
23.97
Forward PE Ratio 13.00
UHS's Forward PE Ratio is ranked higher than
79% of the 62 Companies
in the Global Medical Care industry.

( Industry Median: 21.05 vs. UHS: 13.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 14.75
UHS's PE Ratio without NRI is ranked higher than
83% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. UHS: 14.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
UHS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.26  Med: 15.79 Max: 43.19
Current: 14.75
8.26
43.19
Price-to-Owner-Earnings 17.93
UHS's Price-to-Owner-Earnings is ranked higher than
80% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 27.37 vs. UHS: 17.93 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UHS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.55  Med: 15.93 Max: 412.27
Current: 17.93
7.55
412.27
PB Ratio 2.18
UHS's PB Ratio is ranked higher than
52% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. UHS: 2.18 )
Ranked among companies with meaningful PB Ratio only.
UHS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.16 Max: 3.54
Current: 2.18
1.01
3.54
PS Ratio 1.05
UHS's PS Ratio is ranked higher than
65% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. UHS: 1.05 )
Ranked among companies with meaningful PS Ratio only.
UHS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.8 Max: 1.68
Current: 1.05
0.33
1.68
Price-to-Free-Cash-Flow 23.50
UHS's Price-to-Free-Cash-Flow is ranked higher than
72% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. UHS: 23.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UHS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.57  Med: 15.71 Max: 342.44
Current: 23.5
8.57
342.44
Price-to-Operating-Cash-Flow 10.75
UHS's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 15.16 vs. UHS: 10.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UHS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.2  Med: 8.6 Max: 24.67
Current: 10.75
3.2
24.67
EV-to-EBIT 11.51
UHS's EV-to-EBIT is ranked higher than
83% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 20.05 vs. UHS: 11.51 )
Ranked among companies with meaningful EV-to-EBIT only.
UHS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 11.7 Max: 26
Current: 11.51
6.2
26
EV-to-EBITDA 8.55
UHS's EV-to-EBITDA is ranked higher than
79% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 15.41 vs. UHS: 8.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
UHS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 8.6 Max: 12.2
Current: 8.55
4.3
12.2
EV-to-Revenue 1.43
UHS's EV-to-Revenue is ranked higher than
64% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. UHS: 1.43 )
Ranked among companies with meaningful EV-to-Revenue only.
UHS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.3 Max: 2
Current: 1.43
0.5
2
PEG Ratio 1.80
UHS's PEG Ratio is ranked higher than
68% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 3.06 vs. UHS: 1.80 )
Ranked among companies with meaningful PEG Ratio only.
UHS' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.13 Max: 18
Current: 1.8
0.35
18
Shiller PE Ratio 22.94
UHS's Shiller PE Ratio is ranked higher than
55% of the 51 Companies
in the Global Medical Care industry.

( Industry Median: 29.00 vs. UHS: 22.94 )
Ranked among companies with meaningful Shiller PE Ratio only.
UHS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.14  Med: 21.99 Max: 40.68
Current: 22.94
10.14
40.68
Current Ratio 1.33
UHS's Current Ratio is ranked lower than
59% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. UHS: 1.33 )
Ranked among companies with meaningful Current Ratio only.
UHS' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.41 Max: 1.98
Current: 1.33
0.95
1.98
Quick Ratio 1.23
UHS's Quick Ratio is ranked lower than
58% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. UHS: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
UHS' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.29 Max: 1.78
Current: 1.23
0.82
1.78
Days Inventory 42.28
UHS's Days Inventory is ranked lower than
77% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 15.65 vs. UHS: 42.28 )
Ranked among companies with meaningful Days Inventory only.
UHS' s Days Inventory Range Over the Past 10 Years
Min: 9.58  Med: 42.75 Max: 45.46
Current: 42.28
9.58
45.46
Days Sales Outstanding 52.60
UHS's Days Sales Outstanding is ranked lower than
66% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. UHS: 52.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
UHS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.28  Med: 53.19 Max: 62.41
Current: 52.6
42.28
62.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.36
UHS's Dividend Yield % is ranked lower than
95% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.67 vs. UHS: 0.36 )
Ranked among companies with meaningful Dividend Yield % only.
UHS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.17  Med: 0.43 Max: 0.99
Current: 0.36
0.17
0.99
Dividend Payout Ratio 0.05
UHS's Dividend Payout Ratio is ranked higher than
99% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 0.39 vs. UHS: 0.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
UHS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.06 Max: 0.1
Current: 0.05
0.04
0.1
3-Year Dividend Growth Rate 26.00
UHS's 3-Year Dividend Growth Rate is ranked higher than
77% of the 81 Companies
in the Global Medical Care industry.

( Industry Median: 10.10 vs. UHS: 26.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
UHS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 58.7
Current: 26
0
58.7
Forward Dividend Yield % 0.36
UHS's Forward Dividend Yield % is ranked lower than
94% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 1.95 vs. UHS: 0.36 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.84
UHS's 5-Year Yield-on-Cost % is ranked lower than
86% of the 316 Companies
in the Global Medical Care industry.

( Industry Median: 2.37 vs. UHS: 0.84 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
UHS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.4  Med: 1 Max: 2.31
Current: 0.84
0.4
2.31
3-Year Average Share Buyback Ratio 0.60
UHS's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. UHS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UHS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.3  Med: 1.2 Max: 3.6
Current: 0.6
-6.3
3.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.39
UHS's Price-to-Tangible-Book is ranked lower than
89% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 3.75 vs. UHS: 10.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UHS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.01 Max: 317.57
Current: 10.39
0.84
317.57
Price-to-Intrinsic-Value-Projected-FCF 0.94
UHS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 97 Companies
in the Global Medical Care industry.

( Industry Median: 1.97 vs. UHS: 0.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UHS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.72  Med: 1.16 Max: 33.96
Current: 0.94
0.72
33.96
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.56
UHS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
94% of the 36 Companies
in the Global Medical Care industry.

( Industry Median: 1.65 vs. UHS: 0.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
UHS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.35  Med: 0.75 Max: 2.42
Current: 0.56
0.35
2.42
Price-to-Median-PS-Value 1.31
UHS's Price-to-Median-PS-Value is ranked lower than
76% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. UHS: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UHS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.93 Max: 2.05
Current: 1.31
0.11
2.05
Price-to-Peter-Lynch-Fair-Value 1.62
UHS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
58% of the 59 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. UHS: 1.62 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UHS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.39 Max: 3.71
Current: 1.62
0.4
3.71
Price-to-Graham-Number 2.61
UHS's Price-to-Graham-Number is ranked lower than
64% of the 138 Companies
in the Global Medical Care industry.

( Industry Median: 2.41 vs. UHS: 2.61 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UHS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.56  Med: 1.82 Max: 12.53
Current: 2.61
0.56
12.53
Earnings Yield (Greenblatt) % 8.69
UHS's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.84 vs. UHS: 8.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UHS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 8.5 Max: 16.1
Current: 8.69
3.8
16.1
Forward Rate of Return (Yacktman) % 14.92
UHS's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: 10.98 vs. UHS: 14.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UHS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.4  Med: 18.25 Max: 30.8
Current: 14.92
4.4
30.8

More Statistics

Revenue (TTM) (Mil) $10,110.77
EPS (TTM) $ 7.35
Beta0.83
Short Percentage of Float3.06%
52-Week Range $99.72 - 129.74
Shares Outstanding (Mil)95.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,873 11,571 12,219
EPS ($) 7.61 8.41 9.02
EPS without NRI ($) 7.61 8.41 9.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.40 0.40 0.40
» More Articles for UHS

Headlines

Articles On GuruFocus.com
Universal Health Services, Inc. To Present At The Baird's 2017 Global Healthcare Conference Aug 31 2017 
Universal Health Services, Inc. Announces Dividend Jul 19 2017 
Universal Health Services, Inc. Announces Date For Second Quarter 2017 Earnings Release And Conferen Jul 10 2017 
Universal Health Services, Inc. To Present At The Goldman Sachs 38th Annual Global Healthcare Confer Jun 08 2017 
Universal Health Services, Inc. To Present At The UBS Global Healthcare Conference May 16 2017 
Universal Health Services, Inc. To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conf May 10 2017 
Universal Health Services, Inc. to Present at the Deutsche Bank 42nd Annual Healthcare Conference Apr 27 2017 
Universal Health Services, Inc. Announces Date For First Quarter 2017 Earnings Release And Conferenc Apr 11 2017 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Univers Feb 20 2017 
UNIVERSAL HEALTH 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GE Feb 18 2017 

More From Other Websites
Should You Buy Universal Health Services Inc (UHS)? Sep 13 2017
Is Universal Health Realty Income Trust (UHT) A Buy At Its Current Price? Sep 13 2017
See what the IHS Markit Score report has to say about Universal Health Services Inc. Sep 13 2017
Universal Health (UHS) Grows on Buyouts, Expenses a Drag Sep 11 2017
The Biggest Loser: Envision Healthcare Tumbles 4.2% Sep 06 2017
Universal Health Services, Inc. To Present At The Baird's 2017 Global Healthcare Conference Aug 31 2017
Better Buy: Welltower Inc. vs. Universal Health Services, Inc. Aug 26 2017
Why Is Universal Health (UHS) Down 14.3% Since the Last Earnings Report? Aug 25 2017
Weak patient admissions to bug hospital operators through 2018 Aug 23 2017
ETFs with exposure to Universal Health Services, Inc. : August 21, 2017 Aug 21 2017
Edited Transcript of UHS earnings conference call or presentation 26-Jul-17 1:00pm GMT Aug 11 2017
Universal Health Services, Inc. :UHS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 9, 2017 Aug 09 2017
Universal Health Services, Inc. – Value Analysis (NYSE:UHS) : August 8, 2017 Aug 08 2017
Earnings Review and Free Research Report: Universal Health Services’ Quarterly Revenue Grew 7.5% Aug 03 2017
LifePoint misses revenue estimates, cuts FY forecasts Aug 01 2017
Universal Health Services, Inc. breached its 50 day moving average in a Bearish Manner : UHS-US :... Jul 27 2017
Universal Health (UHS) Q2 Earnings & Revenues Lag Estimates Jul 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}